JPS58225017A - 脱ガン剤 - Google Patents
脱ガン剤Info
- Publication number
- JPS58225017A JPS58225017A JP10851782A JP10851782A JPS58225017A JP S58225017 A JPS58225017 A JP S58225017A JP 10851782 A JP10851782 A JP 10851782A JP 10851782 A JP10851782 A JP 10851782A JP S58225017 A JPS58225017 A JP S58225017A
- Authority
- JP
- Japan
- Prior art keywords
- active ingredient
- benzisothiazole
- agent
- xylene
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 13
- 201000011510 cancer Diseases 0.000 title claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 abstract description 11
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 abstract description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 abstract description 7
- 239000008096 xylene Substances 0.000 abstract description 7
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical class C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 abstract description 3
- VLRWWADMWHAHFZ-UHFFFAOYSA-N 2-benzyl-4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1CC1=CC=CC=C1 VLRWWADMWHAHFZ-UHFFFAOYSA-N 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 238000004440 column chromatography Methods 0.000 abstract description 2
- 238000010992 reflux Methods 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
- PDEMCBLTVSFORZ-UHFFFAOYSA-N 5-chloro-3-phenyl-2,1-benzothiazole Chemical compound C=12C=C(Cl)C=CC2=NSC=1C1=CC=CC=C1 PDEMCBLTVSFORZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000007832 Na2SO4 Substances 0.000 abstract 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001902 propagating effect Effects 0.000 abstract 1
- 229910052938 sodium sulfate Inorganic materials 0.000 abstract 1
- 235000011152 sodium sulphate Nutrition 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000008099 melanin synthesis Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229940123414 Folate antagonist Drugs 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Natural products N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004105 Penicillin G potassium Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- -1 folate antagonists Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000019368 penicillin G potassium Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Landscapes
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10851782A JPS58225017A (ja) | 1982-06-25 | 1982-06-25 | 脱ガン剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10851782A JPS58225017A (ja) | 1982-06-25 | 1982-06-25 | 脱ガン剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58225017A true JPS58225017A (ja) | 1983-12-27 |
| JPH0355447B2 JPH0355447B2 (enrdf_load_stackoverflow) | 1991-08-23 |
Family
ID=14486795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10851782A Granted JPS58225017A (ja) | 1982-06-25 | 1982-06-25 | 脱ガン剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58225017A (enrdf_load_stackoverflow) |
-
1982
- 1982-06-25 JP JP10851782A patent/JPS58225017A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0355447B2 (enrdf_load_stackoverflow) | 1991-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104039775A (zh) | Atp-结合盒转运蛋白的调节剂 | |
| JP5681226B2 (ja) | メチルフェニデート誘導体を含む治療剤 | |
| Kitamura et al. | Regulation of mast cell differentiation | |
| JP5552575B2 (ja) | アルツハイマー病治療用医薬の製造におけるα−マンゴスチンの使用 | |
| CN104650034A (zh) | 一种稳定的阿西替尼化合物 | |
| JP2023510291A (ja) | 幹細胞の機能強化用組成物 | |
| JPS58225017A (ja) | 脱ガン剤 | |
| JPH01228965A (ja) | 縮合キノリン系化合物及び縮合アクリジン系化合物、それらの製造法ならびにそれらの化合物を有効成分とする抗癌剤 | |
| JP2008127325A (ja) | リン酸化ｍｂｐ産生促進剤 | |
| CN106831573A (zh) | (n‑1,2,3,4‑四氢异喹啉基)‑阿魏酰胺化合物、制备方法及其应用 | |
| CN117362255A (zh) | 一种去氢木香内酯衍生物及其制备方法与应用 | |
| CN111840278B (zh) | 化合物与维生素e的组合在制备抗衰老药物或者化妆品中的用途 | |
| CN104622874B (zh) | Ccr4拮抗剂在抑制癌生长及转移中的应用 | |
| CN105412089B (zh) | 化合物vs1在制备抗非小细胞肺癌药物中的应用 | |
| AU757489B2 (en) | Method for inhibiting cytokine production by cells | |
| CN102296056B (zh) | 分枝杆菌噬菌体d29颗粒及其制备方法和应用 | |
| CN107320710B (zh) | 脑蛋白水解物制剂及其设计方法 | |
| PL154026B1 (en) | Method of obtaining derivativies of methylene dioxyphenanthrene | |
| US20040102365A1 (en) | Pharmaceutical composition for prevention and remedy of osteoporosis | |
| Johnson et al. | Two populations of heterozygote erythrocytes in moderate hypoxanthine guanine phosphoribosyltransferase deficiency | |
| Spina et al. | The role of platelet activating factor in allergic inflammation | |
| CN115006382A (zh) | 肉豆蔻酸在制备用于抗老年性骨质疏松药物中的应用 | |
| CN112245433B (zh) | 依克多因类物质在制备防治缺血性脑卒中药物中的应用 | |
| CN112587530B (zh) | 巴瑞克替尼的药物新用途 | |
| US20250221997A1 (en) | Tyk2 inhibitor formulations and methods of making the same |